Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Altered enzymatic activit… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Altered enzymatic activity and allele frequency of OMI/HTRA2 in Alzheimer's disease.

Artikel i vetenskaplig tidskrift
Författare Marie Westerlund
Homira Behbahani
Sandra Gellhaar
Charlotte Forsell
Andrea Carmine Belin
Anna Anvret
Anna Zettergren
Hans Nissbrandt
Charlotta Lind
Olof Sydow
Caroline Graff
Lars Olson
Maria Ankarcrona
Dagmar Galter
Publicerad i The FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Volym 25
Nummer/häfte 4
Sidor 1345-52
ISSN 1530-6860
Publiceringsår 2011
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi
Sidor 1345-52
Språk en
Länkar dx.doi.org/10.1096/fj.10-163402
Ämnesord Aged, Alzheimer Disease, genetics, Case-Control Studies, Cerebral Cortex, enzymology, Gene Frequency, Hippocampus, enzymology, Humans, Middle Aged, Mitochondrial Proteins, genetics, metabolism, Mutation, Missense, Parkinson Disease, genetics, Serine Endopeptidases, genetics, metabolism
Ämneskategorier Medicin och Hälsovetenskap

Sammanfattning

The serine-protease OMI/HTRA2, required for several cellular processes, including mitochondrial function, autophagy, chaperone activity, and apoptosis, has been implicated in the pathogenesis of both Alzheimer's disease (AD) and Parkinson's disease (PD). Western blot quantification of OMI/HTRA2 in frontal cortex of patients with AD (n=10) and control subjects (n=10) in two separate materials indicated reduced processed (active, 35 kDa) OMI/HTRA2 levels, whereas unprocessed (50 kDa) enzyme levels were not significantly different between the groups. Interestingly, the specific protease activity of OMI/HTRA2 was found to be significantly increased in patients with AD (n=10) compared to matched control subjects (n=10) in frontal cortex in two separate materials. Comparison of OMI/HTRA2 mRNA levels in frontal cortex and hippocampus, two brain areas particularly affected by AD, indicated similar levels in patients with AD (n=10) and matched control subjects (n=10). In addition, we analyzed the occurrence of the OMI/HTRA2 variants A141S and G399S in Swedish case-control materials for AD and PD and found a weak association of A141S with AD, but not with PD. In conclusion, our genetic, histological, and biochemical findings give further support to an involvement of OMI/HTRA2 in the pathology of AD; however, further studies are needed to clarify the role of this gene in neurodegeneration.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?